{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003910","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.613571+00:00","generated_at":"2026-06-07T02:01:44.253460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs","bullets":["Reaffirms 2023 total, neuroscience, and oncology revenue guidance range.","Xywav, Epidiolex, and Rylaze expected to have combined double-digit revenue growth in 2024.","High-sodium oxybate authorized generic royalty revenue expected to grow in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003910","json":"https://secwatch.observer/filing/0001193125-24-003910.json","markdown":"https://secwatch.observer/filing/0001193125-24-003910.md","text":"https://secwatch.observer/filing/0001193125-24-003910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/d636118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:01:44.253460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17b2f6cc2e1fda1f293f2b2448d87d8449ac7774","claim":"Jazz Pharmaceuticals plc updated its the year ended December 31, 2024 guidance (initiated).","evidence_excerpt":"the Company's expectations that its key growth drivers, Xywav, Epidiolex, and Rylaze, are expected to have combined double-digit percentage revenue growth in 2024, and (iii) the Company's expectations with respect to the growth of high-sodium oxybate authorized generic royalty revenue for the year ended December 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2024"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"1dcb2a371181dda57e52f9fd24c185cf0f28794c","claim":"Jazz Pharmaceuticals plc updated its the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance range for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312524003910/0001193125-24-003910-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}